SCLX
Scilex Holding Co
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Scilex has 12 disclosed suppliers and 5 disclosed customers in SEC filings.
Scilex Holding Co
1.95
SentenceIn the years ended December 31, 2020, and 2021, and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods.
basisSCLX FY2025 revenue $30M
SCLX 10-Kaccession 0001193125-26-151455
SentencePrior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health 105, for ZTlido distribution in the United States.
SCLX 10-Kaccession 0001193125-26-151455
SentenceHistorically, we have purchased our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SP-102, from Genzyme pursuant to a supply agreement, which terminated as of May 31, 2024.
SCLX 10-Kaccession 0001193125-26-151455
SentenceIn February 2013, Scilex Pharma became a party to a product development agreement (as amended, the "Product Development Agreement") with Itochu and Oishi (together, the "Developers"), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103, for Scilex Pharma.
SCLX 10-Kaccession 0001193125-26-151455
SentenceItochu agreed to purchase Products from Oishi and handle the shipping of the Products.
SCLX 10-Kaccession 0001193125-26-151455
SentencePursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a "Lifecore Statement of Work").
SCLX 10-Kaccession 0001193125-26-151455
SentenceIn April 2025, Scilex Bio, Inc. ("Scilex Bio"), our subsidiary, signed an agreement with NeuroBiogen Company ("NBG") to grant Scilex Bio an exclusive worldwide license to the franchise KDS2010 drug candidate to develop and commercialize in metabolic diseases (including obesity and type 2 diabetes) and neurodegenerative diseases, including Alzheimer's, Parkinson's and other CNS diseases.
SCLX 10-Kaccession 0001193125-26-151455
SentenceIn February 2013, Scilex Pharma became a party to a product development agreement (as amended, the "Product Development Agreement") with Itochu and Oishi (together, the "Developers"), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103, for Scilex Pharma.
SCLX 10-Kaccession 0001193125-26-151455
SentenceIn June 2022, we entered into the Romeg License Agreement with Romeg, which agreement was subsequently amended in January 2025, to acquire certain rights to GLOPERBA and the exclusive license to use the trademark "GLOPERBA®".
SCLX 10-Kaccession 0001193125-26-151455
SentenceWe acquired certain rights to GLOPERBA and the exclusive license to use the trademark "GLOPERBA®", pursuant to a License and Commercialization Agreement we entered into with RxOmeg Therapeutics LLC (a/k/a Romeg Therapeutics, LLC) ("Romeg"), dated as of June 14, 2022, which agreement was subsequently amended on January 16, 2025 (such agreement, as so amended, the "Romeg License Agreement").
SCLX 10-Kaccession 0001193125-26-151455
SentenceWe acquired SP-102 from Semnur Pharmaceuticals, Inc. ("Semnur") in March 2019 and are developing SP-102 to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by off-label epidural steroid injections ("ESI"), which are administered over 12 million times annually in the United States.
SCLX 10-Kaccession 0001193125-26-151455
SentenceSubsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to SP-104 and on May 12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the "Bill of Sale"), pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the SP-104 Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento's rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the "SP-104 Acquisition").
SCLX 10-Kaccession 0001193125-26-151455
SentenceOn May 12, 2025, Scilex signed an agreement with Syneos Health Commercial Services, LLC to provide sales force outsourcing activities which the outsourced sales force would continue to dedicate all of their efforts to Scilex products.
SCLX 10-Kaccession 0001193125-26-151455
SentenceWe currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation ("McKesson"), Cardinal Health 110, LLC ("Cardinal Health 110") and AmerisourceBergen Corporation ("AmerisourceBergen").
SCLX 10-Kaccession 0001193125-26-151455
SentenceWe currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation ("McKesson"), Cardinal Health 110, LLC ("Cardinal Health 110") and AmerisourceBergen Corporation ("AmerisourceBergen").
SCLX 10-Kaccession 0001193125-26-151455
SentenceIn November 2024, we delivered the Additional Product to Endeavor and fully satisfied the remaining obligations in respect of the FSF Deposit.
SCLX 10-Kaccession 0001193125-26-151455
SentenceWe currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation ("McKesson"), Cardinal Health 110, LLC ("Cardinal Health 110") and AmerisourceBergen Corporation ("AmerisourceBergen").
SCLX 10-Kaccession 0001193125-26-151455
Expected move
No implied move.